drugset / Trial / NCT07277231
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to investigate the efficacy and safety of fixed-duration sonrotoclax (also known as BGB-11417) plus zanubrutinib (also known as BGB-3111) (SZ) compared with fixed-duration of venetoclax plus acalabrutinib (AV) in participants with previously untreated chronic lymphocytic leukemia (CLL).
Timeline
- Start
- 2026-01-22
- Primary completion
- 2031-02
- Completion
- 2031-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Acalabrutinib | Small molecule | — | Oral |
| Subject | Sonrotoclax | Other / unclassified | — | Oral |
| Comparator | Venetoclax | Small molecule | — | Oral |
| Subject | Zanubrutinib | Small molecule | — | Oral |